<DOC>
	<DOCNO>NCT01515774</DOCNO>
	<brief_summary>1 . In order observe benefit , side effect , patient preference Mirapex ER use once-daily ( QD ) twice-daily ( BID ) dose 2 . In order estimate conversion rate dopamine agonists Mirapex ER</brief_summary>
	<brief_title>Study Observe Effect Mirapex ERÂ® Once-daily ( QD ) Versus Twice-daily ( BID )</brief_title>
	<detailed_description>1 . Study subject : Parkinson disease Requip Mirapex consider change Mirapex ER 2 . Cross study design : - Group 1 : Once daily dose 2 month BID divide dose 2 month - Group 2 : BID divide dose 2 month QD dose 2 month 3 . Dose adjustment may do first 4 week . 4 . Compare benefit , side effect , patient preference QD v BID dosing</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>1 . Age : 3080 2 . Parkinson disease 3 . On dopamine agonist ( Requip Mirapex ) consider change Mirapex ER 4 . On stable antiparkinsonian medication least 4 week 5. Who sign consent study 1. Who less 2 mg Requip 0.375 mg Mirapex 2. Who dementia , psychosis , major depression serious neurological medical problem 3. Who allergic similar medication 4. Who history heavy metal poison 5. Who othe clinical trial medication within last 4 week 6. Who pregnant lactate 7. Who consider eligible investigator</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Pramipexole</keyword>
</DOC>